Choosing between AbbVie (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY) requires weighing high-growth immunology assets against deep value as both drugmakers navigate a shifting landscape of patent expirations and drug pricing reforms. AbbVie focuses on specialty immunology and aesthetics, pivoting past its Humira legacy. Bristol-Myers Squibb emphasizes oncology and cardiovascular health while transitioning to its next-generation pipeline.
Both companies are major players in the pharmaceutical industry, appealing to income-seeking investors through consistent dividends and stable cash flows. AbbVie is a global biopharmaceutical company that delivers innovative medicines across roughly 180 countries. The company is a major player among pharmaceutical stocks, maintaining manufacturing facilities in roughly 20 countries.
Its primary U.S. sales are concentrated among three major wholesale distributors, including McKesson Corporation, Cardinal Health, and Cencora, though no single wholesaler accounted for more than 43% of total U.S. gross revenues in 2025. In FY 2025, revenue reached nearly $61.2 billion, reflecting growth of approximately 8.6% compared to the prior year. The company reported net income of close to $4.2 billion during this period.
This growth was largely supported by the continued expansion of newer drug labels, which have helped offset the revenue erosion from older products facing competition. As of its December 2025 balance sheet, the debt-to-equity ratio is -21.1x, which means total liabilities exceed shareholder equity. The current ratio, which measures the ability to cover short-term obligations with short-term assets, is approximately 0.7x.
Free cash flow, calculated as cash from operations minus capital expenditures, was nearly $17.8 billion for the year. Bristol-Myers Squibb is a global biopharmaceutical leader focused on serious diseases in oncology, hematology, and cardiovascular health. The company sells its products to wholesalers, specialty pharmacies, and government agencies worldwide.
In the U.S., the company maintains distribution service agreements with nearly all direct wholesaler customers, and these agreements are currently set to expire in June 2027. In FY 2025, revenue reached close to $48.2 billion, representing a slight decrease of roughly 0.2% over the previous year. Despite the flat revenue growth, the company achieved net income of approximately $7.1 billion.
Extract — continue reading at the source.
